MARKET

CMPS

CMPS

Compass Pathways Plc
NASDAQ
11.42
+0.16
+1.43%
Opening 10:51 06/10 EDT
OPEN
11.19
PREV CLOSE
11.26
HIGH
11.79
LOW
11.13
VOLUME
729.66K
TURNOVER
--
52 WEEK HIGH
14.76
52 WEEK LOW
2.250
MARKET CAP
1.54B
P/E (TTM)
-5.6978
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CMPS last week (0601-0605)?
Weekly Report · 2d ago
Compass Pathways targets late 2027 approval for treatment-resistant depression psychedelic therapy
PUBT · 5d ago
BRIEF-Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Reuters · 5d ago
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 5d ago
Assessing COMPASS Pathways (CMPS) Valuation After Positive Phase 3 COMP360 Trial Milestone
Simply Wall St · 5d ago
Hypha Labs flags cannabis-like growth pattern emerging in psychedelic industry
PUBT · 6d ago
COMPASS Pathways Reaffirmed at Buy as Analyst Highlights Late-Stage Data, Commercial Readiness and Keeps $23 Price Target Unchanged
TipRanks · 06/02 11:36
Is COMPASS Pathways (CMPS) Recasting Its Commercialization Strategy With Kathleen Tregoning’s Board Appointment?
Simply Wall St · 06/01 09:23
More
About CMPS
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Webull offers Compass Pathways PLC (ADR) stock information, including NASDAQ: CMPS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CMPS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CMPS stock methods without spending real money on the virtual paper trading platform.